Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer · 2023-10 · 11 (10) · e007699
DOI: 10.1136/jitc-2023-007699 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 29.10.2023. Verfasst von Patrick T Magahis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medical College, New York, New York, USA. Hauptthemen laut MEDLINE: Helicobacter pylori, Stomach Neoplasms, Helicobacter Infections. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, NCI NIH HHS, National Cancer Institute of the National Institutes of Health.
Abstract (Originalsprache)
Background
Gut microbiota composition can influence cancer immunotherapy response. Recent evidence suggests Helicobacter pylori infection may reduce immune checkpoint inhibitor (ICI) efficacy in lung cancer and melanoma, but thorough characterization of this association in patients with gastric cancer is lacking. We aimed to determine the impact of H. pylori on survival in this population.
Methods
This single-center, retrospective study included all ICI-treated individuals with metastatic gastric cancer and documented H. pylori status at Memorial Sloan Kettering between July 2013 and October 2021. H. pylori -positive status was defined as history of infection obtained via breath test, stool antigen test, histopathology, and/or chart documentation. Negative status was defined as explicitly negative testing, histopathology, and/or chart documentation. Primary outcomes were progression-free survival (PFS) and overall survival (OS).
Results
Of 215 included patients, 49 had documented history of H. pylori infection. Compared with H. pylori- negative patients, positive individuals tended to be younger, non-white, and Hispanic with non-cardia and intestinal-type gastric cancer. H. pylori- positive patients had significantly shorter median PFS (3.2 vs 6.8 months, HR 1.96, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Weill Cornell Medical College, New York, New York, USA.
- Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Gastroenterology, Hepatology, and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Gastroenterology, Hepatology, and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA laszkowm@mskcc.org.
ORCID-Profile: Patrick T Magahis, Darren Cowzer, David Faleck
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
- National Cancer Institute of the National Institutes of Health
- NIDDK of the National Institutes of Health
- NIH/NCI Cancer Center
Zitieren
APA
Magahis, P. T., Maron, S. B., Cowzer, D., King, S., Schattner, M., Janjigian, Y., Faleck, D., & Laszkowska, M. (2023). Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer, 11(10), e007699. https://doi.org/10.1136/jitc-2023-007699
Vancouver
Magahis PT, Maron SB, Cowzer D, King S, Schattner M, Janjigian Y, et al. Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 2023;11(10):e007699. doi:10.1136/jitc-2023-007699
BibTeX
@article{Magahis2023,
author = {Magahis, Patrick T and Maron, Steven B and Cowzer, Darren and King, Stephanie and Schattner, Mark and Janjigian, Yelena and Faleck, David and Laszkowska, Monika},
title = {Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {10},
pages = {e007699},
doi = {10.1136/jitc-2023-007699}
}
EUVIMED